Intervention Protocol

Medical therapeutic agents for Wilson's disease

  1. Belal Firwana1,*,
  2. Nazir Ibrahim2,
  3. Rokana Taftaf3,
  4. Anas Shaneh Saz3,
  5. Mohamad Bassam Sonbol3,
  6. Rim Hasan3,
  7. Christian Gluud4

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 16 MAR 2011

Assessed as up-to-date: 26 DEC 2010

DOI: 10.1002/14651858.CD009057


How to Cite

Firwana B, Ibrahim N, Taftaf R, Shaneh Saz A, Sonbol MB, Hasan R, Gluud C. Medical therapeutic agents for Wilson's disease (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD009057. DOI: 10.1002/14651858.CD009057.

Author Information

  1. 1

    Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic

  2. 2

    Alkalamon University, Damascus, Syrian Arab Republic

  3. 3

    Damascus University, Faculty of Medicine, Damascus, Syrian Arab Republic

  4. 4

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Belal Firwana, Faculty of Medicine, Damascus University, P.O.Box 12503, Damascus, Syrian Arab Republic. b.firwana@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 16 MAR 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the beneficial and harmful effects of copper-chelating agents in treating patients with Wilson's disease.